Navigation Links
Review finds conflicts of interest in many cancer studies
Date:5/10/2009

A new analysis finds that a considerable number of clinical cancer studies published in respected medical journals have financial connections to pharmaceutical companies. Published in the June 15, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that conflicts of interest may cause some researchers to report biased results that are favorable to companies.

Ties between clinical researchers and companies that make medical devices and drugs have become increasingly complex and controversial, particularly as more researchers compete for scarce federal research funds. In addition to using industry money to support their research, some investigators receive consulting fees, own stock and hold positions within companies that profit from selling the very products they are investigating. These conflicts of interest have raised concerns that studies with ties to industry are biased and are not designed to provide a true test of medical therapies. Many medical journals now require researchers to disclose potential conflicts of interest in the articles they submit for publication.

To get sense of the frequency and impact of conflicts of interest in clinical cancer research, Dr. Reshma Jagsi of the University of Michigan and colleagues reviewed cancer studies appearing in eight highly regarded journals in 2006. These journals included the New England Journal of Medicine; JAMA; the Lancet; the Journal of Clinical Oncology; the Journal of the National Cancer Institute; Lancet Oncology; Clinical Cancer Research; and CANCER.

Of the 1,534 cancer studies identified in these journals, 29 percent had conflicts of interest that were apparent from review of published author declarations and authorship lists (including industry funding, consulting fees to authors, co-authorship by industry employees, etc.), and 17 percent declared industry funding. Conflicts of interest were most often found in articles with primary authors from departments in medical oncology (45 percent), those from North America (33 percent), and those with male first and senior authors (37 percent).

According to the authors, randomized clinical trials that assessed patient survival were more likely to report a survival advantage associated with the intervention when a conflict of interest was present. These trials are the foundation by which drugs, technologies, diagnostic tests, etc. get approved for use in the clinic and therefore shape the way oncologists practice medicine.

The findings also show that studies with industry funding were more likely to focus on treatment than studies without industry funding (62 percent vs. 36 percent). They were less likely than studies not declaring industry funding to focus on epidemiology, prevention, risk factors, screening or diagnostic methods (20 percent vs. 47 percent).

This analysis revealed that conflicts of interest exist in a considerable number of clinical cancer research articles published in important journals. The authors noted that "attempts to disentangle the cancer research effort from industry merit further attention, and journals should embrace both rigorous standards of disclosure and heightened scrutiny when conflicts exist."


'/>"/>

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society
Source:Eurekalert

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
3. Arbios Systems, Incs Q2/07 Analyst Review Issued by Scimitar Equity Research, Inc.
4. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
5. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
6. Peer-Reviewed, Online Database Showcases Local, County and State Pandemic Planning
7. InstaCare Corp. Reviewing M&A Plans
8. CCF Reviews Contents of SCHIP Reauthorization Bill Legislation Places SCHIP on Solid Path
9. Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Managements Internal Control Review Efforts and on Legal Proceedings
10. Multicountry review shows that Bug Buster Kits reduce head lice and social stigma
11. MaxLife Fund Corp. retains the Law firm, Anslow & Jaclin, LLP of Manalapan, N.J., to review MaxLife Fund Corp. options to be listed on the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... New York, New York (PRWEB) , ... May 24, 2017 , ... ... and general vascular surgery in New York City. He is known for ... his broad specialization in vascular surgery, Dr. Benvenisty holds sub-specialty training in treating renovascular ...
(Date:5/24/2017)... ... 2017 , ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now ... a referral. Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take ... Patients no longer need to feel the esthetic effects of wires and brackets when ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... II of the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. As a ... advancements in his field by attending numerous CE courses each year. His recent ...
(Date:5/24/2017)... ... 24, 2017 , ... If you are thinking of a visit to San Francisco , ... is the perfect time to visit. , Business Architecture Associates is pleased to offer 5 ... individuals, as a 4-½ day package for individuals, and as 4-½ day corporate package for ...
(Date:5/24/2017)... Falls, Wisconsin (PRWEB) , ... May 24, 2017 ... ... leader in clean label food ingredient solutions for the food and beverage industry ... factor in food ingredient statements during the purchasing decision process. As a result, ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... JERUSALEM , May 9, 2017  Oramed ... www.oramed.com ), a clinical-stage pharmaceutical company focused on ... today that the Canadian Intellectual Property Office has ... for Oral Administration of Exenatide". The patent covers ... analog. GLP-1 is an incretin hormone ...
(Date:5/6/2017)... 5, 2017   Provista , a proven leader in ... customers, today announced Jim Cunniff as the company,s ... and business experience to Provista, including most recently serving as ... California . He assumed his new role with ... great fit for Provista," says Jody Hatcher , president, ...
(Date:5/4/2017)... 2017  A recent study published in the ... light as a means of disinfection anesthesia workstations ... bioburden on anesthesia workstations. In the study, UVC ... medical equipment surfaces contaminated with three (3) organisms ... study further validates the body of literature supporting ...
Breaking Medicine Technology: